Odyssey Therapeutics Files for $232 Million Nasdaq IPO to Advance Autoimmune Disease Pipeline
核心洞察
Odyssey Therapeutics (搜索), a clinical-stage biotech developing precision therapies for autoimmune diseases (搜索), has filed for a $232 million IPO on Nasdaq under ticker "ODTX."
The company's lead program OD-001 (搜索), an oral RIPK2 (搜索) inhibitor, achieved proof-of-concept in Phase 2a trials for ulcerative colitis (搜索) and is advancing toward Phase 2b monotherapy studies.
IPO proceeds will fund advancement of OD-001 (搜索) through Phase 2a combination trials with vedolizumab and Phase 2b monotherapy readouts, plus development of SLC15A4 (搜索) inhibitor OD-002 (搜索).
Odyssey Therapeutics (搜索), a clinical-stage biopharmaceutical company developing targeted therapies for autoimmune and inflammatory diseases (搜索), has filed for an initial public offering on the Nasdaq Capital Market. The Boston-based company plans to raise $232 million by offering 13.2 million shares at a price range of $16 to $18 under the ticker symbol "ODTX."
The IPO proceeds will primarily advance Odyssey's lead program OD-001 (搜索), an oral RIPK2 (搜索) scaffolding inhibitor that has demonstrated proof-of-concept in Phase 2a trials for ulcerative colitis (搜索). The company plans to advance OD-001 toward a Phase 2b monotherapy study and a Phase 2a combination study with vedolizumab. Additional funding will support the development of OD-002 (搜索), an oral SLC15A4 (搜索) inhibitor currently in IND-enabling studies, through Phase 1/2a trials.
Pipeline Targeting Upstream Immune Pathways
Odyssey's approach focuses on upstream innate immune nodes, including RIPK2 (搜索), SLC15A4 (搜索), and IRAK4 (搜索) pathways, with potential to address therapeutic ceilings and resistance seen with current treatments. The company's second program, OD-002 (搜索), is designed to block nucleic acid-driven TLR7 (搜索)/8/9 signaling for interferonopathies such as systemic lupus erythematosus (搜索) (SLE) and cutaneous lupus erythematosus (搜索) (CLE).
Beyond these lead programs, Odyssey is developing OD-003 (搜索), a VHH-based TNFR2 (搜索) agonist aimed at selectively expanding and stabilizing regulatory T cells, and OD-004 (搜索), a bispecific antagonist of TSLP (搜索) and IL-33 (搜索) for respiratory diseases. The company also has a small-molecule IRAK4 (搜索) scaffolding inhibitor targeting the myddosome in development and collaborates with Terray Therapeutics (搜索) on an IRF5 inhibitor program.
Market Opportunity and Competitive Landscape
The company operates in a substantial market opportunity, with inflammatory disease therapies exceeding $100 billion globally. The inflammatory bowel disease (搜索) (IBD) market specifically was approximately $25 billion globally in 2025 and is expected to reach $40 billion by 2032, with the U.S. market growing from $17 billion to $31 billion over the same period.
Current established mechanisms of action in the autoimmune space include anti-TNFs, anti-IL-23s, integrin blockers, JAK and S1P1 inhibitors. The company also notes emerging approaches including TL1A, miR-124, and oral integrins in development. Industry trends are shifting toward innate immunity targets, combination regimens, AI/ML-enabled discovery, and next-generation protein therapeutics including bispecifics and VHH-based therapies.
Technology Platform and Operations
Odyssey leverages artificial intelligence and machine learning across small molecule and protein discovery, structural biology, and translational platforms. The company plans globally distributed trials and currently operates clinical studies spanning 18 sites across seven countries including Australia, Canada, Jordan, Moldova, New Zealand, Poland, and Ukraine.
Founded in 2021, Odyssey has raised approximately $726.5 million since inception and employs 100 full-time employees as of March 31, 2026. The company operates from headquarters in Boston, Massachusetts, with additional research facilities in Ann Arbor, Michigan.
Financial Performance and Leadership
For the 12 months ended December 31, 2025, Odyssey reported $2.98 million in collaboration revenue, representing a 33.5% decrease from $4.47 million in 2024. The company reported an operating loss of $157.1 million and net loss of $148.6 million in 2025.
The company is led by President and CEO Gary D. Glick, Ph.D., a biotech founder with prior leadership experience at IFM Therapeutics and Scorpion Therapeutics. Board Chair Jeffrey M. Leiden, M.D., Ph.D., serves as Executive Chairman and former CEO of Vertex, having previously led the HUMIRA program at Abbott (搜索).
The IPO is being led by J.P. Morgan, TD Cowen, Cantor Fitzgerald, Wedbush PacGrow, and Oppenheimer & Co. as joint bookrunners. The offering is expected to price during the week of May 4, 2026.